

BioPharma Dealmakers

The world's leading publication that connects life science companies to partners and investors.

biopharmadealmakers.nature.com

SPRINGER NATURE	2
PARTNERING SOLUTIONS	3
WEBCASTS	4
OUR AUDIENCE	5
EDITORIAL CALENDARS	6

AUDIENCE & REACH

Access an unrivalled network of trusted scientific brands

nature
research

SPRINGER NATURE

BMC

**SCIENTIFIC
AMERICAN**

OUR PORTFOLIO*



3,000+
JOURNALS



7 MILLION+
ARTICLES



Our journals rank
#1 in 37 Categories

OUR MONTHLY DIGITAL REACH**



133 MILLION
page views



76 MILLION
sessions



230,000+
third party email subscribers



700,000+
alerts subscribers

OUR AUDIENCE IS HIGHLY QUALIFIED AND INFLUENTIAL***



87%
hold postgraduate qualifications



\$85.8K
average annual budget for research products/
equipment



BioPharma Dealmakers is an online platform, print publication, and webcast format specifically designed to appeal to industry scientists, partnering and licensing executives, and the investment community. Get started now at biopharmadealmakers.nature.com

PRINT

Published quarterly inside *Nature Biotechnology* and *Nature Reviews Drug Discovery*, BioPharma Dealmakers provides your company with the associated benefits of being profiled in Nature-branded publications. Enjoy enduring visibility with a high-profile audience, and the expert support of our editorial team.

nature reviews drug discovery

nature biotechnology

PRINT PROFILE FEATURES

- » Custom profile
- » Distributed with high-impact journals:
 - *Nature Biotechnology*
 - *Nature Reviews Drug Discovery*
- » Access to world-renowned editors

PRINT PROFILE BENEFITS

- » Enduring visibility
- » Quality association
- » Exposure to biotech industry
- » Exposure to drug discovery industry
- » Expert editorial and design support

ADVERTISEMENT FEATURE

Korea Drug Development Fund
www.eng.kddf.org

Propelling Korea's oncology science globally
By supporting research, development and licensing behind its portfolio of companies KDDF is transcending Korean science into breakthrough oncology treatments.

KDDF's achievements

\$1B	590	162	201 billion
invested	grants	licensing programs	total value

KDDF's achievements

Through its portfolio of companies KDDF has achieved a number of major milestones in its oncology history. FDA, Food and Drug Administration (FDA), Ministry of Food and Drug Safety, CD29, cancer drug development.

Anti-PSMA and other immunotoxins typically use an antibody toxin and a linking linker to connect the toxin and antibody. However, enzymes can break the linker and cause side effects.

Those problems led CellBio to create a shorter linker and connect the toxin and antibody without the use of an antibody toxin. These diagnostic and therapeutic immunotoxins are now being developed by Immunocore as a platform for immunotoxins. CellBio is also developing a platform for immunotoxins that can be used to target a wide range of cancer types.

CellBio's achievements

CellBio's platform for immunotoxins is now being developed by Immunocore as a platform for immunotoxins. CellBio is also developing a platform for immunotoxins that can be used to target a wide range of cancer types.

CellBio's achievements

CellBio's platform for immunotoxins is now being developed by Immunocore as a platform for immunotoxins. CellBio is also developing a platform for immunotoxins that can be used to target a wide range of cancer types.

ADVERTISEMENT FEATURE

VCN Biosciences SL
www.vcnbiosciences.com

Oncolytic adenovirus VCN-01 turns cold tumors hot
VCN Biosciences is developing a highly selective, advanced generation of oncolytic adenoviruses.

Integrating historical observations that some cell adhesion molecules are overexpressed in cancer cells, leading to increased proliferation and metastasis, VCN Biosciences has developed a highly selective, advanced generation of oncolytic adenoviruses. VCN-01 targets the integrin $\alpha_5\beta_1$ and is highly selective for cancer cells, leading to increased proliferation and metastasis.

Next steps and partnering

VCN Biosciences is currently in the late preclinical stage and is expected to enter the clinic soon. The company is interested in further exploring the combination of VCN-01 with immunomodulatory agents to enhance its anti-tumor activity. VCN Biosciences is also exploring the combination of VCN-01 with other cancer therapies to enhance its anti-tumor activity.

DIGITAL

The *BioPharma Dealmakers* website is the premier partnering destination for life sciences companies and the investment community. Your digital profile amplifies the momentous impact created by your printed feature, and unlocks powerful networking tools and industry insights through a range of membership benefits.

DIGITAL PROFILE FEATURES

- » Custom profile
- » Industry intelligence
- » Engagement tools
- » Profile enhancements
- » Visibility perks
- » Account insights

DIGITAL PROFILE BENEFITS

- » Rapid access to information
- » Stay ahead of the competition
- » Connect with investors
- » Increase effectiveness
- » Enhance prominence
- » Strengthen your profile with supplemental media

WEBCAST

A *BioPharma Dealmakers* webcast compliments your digital and print presence with a powerful multimedia solution that enables your audience to interact with key people within your organization.

"The webcast was a valuable experience and it helped to raise awareness about our company. We were very happy with the number of attendees and questions from viewers during the webcast." - Mary Marolla, PR Manager, OncoSec Medical


WEBCAST BENEFITS

- » Generate a highly-targeted and qualified leads list
- » Participate in genuine discussions with your target audience
- » Maximize your visibility with branding on all marketing
- » Raise your company's profile to key opinion leaders
- » Position your company as a key player in its field to potential partners, customers and investors
- » Previous webcast topics have included:
 - Fighting infectious diseases
 - Making a name in cancer immunotherapy
 - New innovations in drug delivery technology
 - Advances in precision medicine and genomic sequencing
 - Innovating for ophthalmic diseases

- » Webcast registrants average over 460 per event*


WEBCAST AUDIENCE**

Registrant Industry



- Academia/Hospitals/Non-profits/Government
- Pharma
- Biotech
- Investors/Venture Capital/Family Offices
- Service Providers/Other (e.g. media, consultancy, legal)

Registrant Location



- Americas
- UK/Europe
- Asia/RoW

» [Visit nature.com/webcasts](http://nature.com/webcasts)

EXPLORE OUR AUDIENCE

Make successful connections with senior-level executives, business development leaders, potential clients and research professionals by creating an account with *BioPharma Dealmakers*. All issues of *BioPharma Dealmakers* will appear in *Nature Biotechnology* and *Nature Reviews Drug Discovery*, in print and freely accessible online. Issues of *BioPharma Dealmakers* are also distributed at key partnering and investor events.

nature biotechnology


nature.com/nbt

Nature Biotechnology publishes new concepts in technology/methodology of relevance to the biological, biomedical, agricultural and environmental sciences as well as covers the commercial, political, ethical, legal, and societal aspects of this research.*

JOURNAL METRICS*

Total Cites:.....**60,971**
 Industry Rank:.....**2/162**
#2 Journal in Biotechnology & Applied Microbiology
 Impact Factor:.....**31.864**
 5-Year Impact Factor:.....**45.117**
 Immediacy Index:.....**9.41**
 Eigenfactor Score:.....**0.15814**
 Article Influence Score:.....**22.167**

GLOBAL AUDIENCE**



nature reviews drug discovery


nature.com/nrdd

Nature Reviews Drug Discovery informs researchers of the science and business within the pharmaceutical and drug research industries.*

JOURNAL METRICS*

Total Cites:.....**32,266**
 Industry Rank:.....**1/267**
#1 Journal in Pharmacology & Pharmacy
 Impact Factor:.....**57.618**
 5-Year Impact Factor:.....**58.884**
 Immediacy Index:.....**13.306**
 Eigenfactor Score:.....**0.05489**
 Article Influence Score:.....**20.88**

GLOBAL AUDIENCE**



COMBINED READER PROFILE

TOP JOB FUNCTIONS†



Research/Labs
44%



Academic
37%




Clinicians/Healthcare
5%



Business/Investment
4%

TOP PLACE OF WORK†



Members Location:***



AVERAGE SITE VIEWS PER MONTH***
10.2K

CALENDARS 2020

Editorial features focus on the partnering landscape, burgeoning therapeutic areas and geographical regions of interest.

BIOPHARMA DEALMAKERS 2020 EDITORIAL CALENDAR

Issue Date	Editorial Themes	Conference Distribution*	Booking Deadline
March	Oncology Biopharma deals/Industry insights		January 8
June	Infectious diseases and vaccines Biopharma deals/Industry insights Regenerative medicine (curative biologics, gene and cell therapies)		March 19
September	Immuno-oncology Antibody technologies Central nervous system diseases	BioPharm America (September 11-12, Boston, USA) NLS Days (September 8-10, Malmo, Sweden) Bio-Europe (October 26-28, Munich, Germany) Society for Neuroscience annual meeting (October 24-28, Washington, USA)	June 18
December	Cardiovascular and respiratory diseases Inflammation-based diseases (microbiome, gastrointestinal, dermatology) Deals round up of 2020	JP Morgan/Biotech Showcase (2021 San Francisco, USA) BIO CEO & Investors Conference	September 18



MedTech Dealmakers is published inside Nature Medicine in print, in addition to Nature Biotechnology and Nature Reviews Drug Discovery.


Issue Date	Editorial Themes	Conference Distribution*	Booking Deadline
April	Medtech deals review	Bio International Convention (June 8-11, San Diego, USA)	January 23

**nature
medicine**
nature.com/nm

JOURNAL METRICS*

Total Cites:..... **79,243**
#1 journal in Medicine, Research & Experimental
 Impact Factor:..... **30.641**
 5-Year Impact Factor:..... **34.848**
 Immediacy Index:..... **7.847**
 Eigenfactor Score:..... **0.16284**
 Article Influence Score:..... **15.662**

GLOBAL AUDIENCE



PRINT
1,068 print circulation
16,110 print readership[^]

*Conference distribution is subject to change. Contact your Account Manager for up-to-date information.

Contact us

biopharmadealmakers.nature.com

Claire Thompson

Head of Business Development
+44 207 418 5708
c.thompson@nature.com

USA

Veronica Zacatenco

Business Development Manager
+1 212 451 8573
veronica.zacatenco@us.nature.com

Carmen Ramirez

Account Executive
+1 212 451 8472
carmen.ramirez@us.nature.com

EUROPE

Rebecca Djaic

Account Executive
+44 739 231 5386
Rebecca.djaic@springernature.com